최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0184406 (2011-07-15) |
등록번호 | US-8293367 (2012-10-23) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 2 인용 특허 : 800 |
Nano-constructscomprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.
1. A nano-construct comprising (a) a core material comprising a polymer,(b) a nanoshell formed around the core material, and(c) optionally a bioactive agent,wherein the polymer is a degradable polymer or a non-degradable polymer and the non-degradable polymer is selected from the group consisting of
1. A nano-construct comprising (a) a core material comprising a polymer,(b) a nanoshell formed around the core material, and(c) optionally a bioactive agent,wherein the polymer is a degradable polymer or a non-degradable polymer and the non-degradable polymer is selected from the group consisting of poly(N-(3-aminopropyl)methacrylamide), a copolymer of N-(3-aminopropyl)methacrylamide, and a combination thereof, andwherein the nanoshell comprises an electrically conductive material. 2. The nano-construct of claim 1 wherein the nanoshell comprises gold. 3. The nano-construct of claim 2 wherein the gold nanoshell has a thickness between about 5 and about 25 nm. 4. The nano-construct of claim 1 wherein the core material has a size in the range between about 150 nm to about 2000 nm. 5. The nano-construct of claim 4 wherein the gold nanoshell surrounding the core material is porous to the optional bioactive agent. 6. The nano-construct of claim 1, wherein the nanoshell comprises iron, iron based alloys, magnesium, magnesium alloys, zinc, calcium, tungsten, alloys based on these metals, or combinations thereof. 7. The nano-construct of claim 1, wherein the electrically conductive material comprises an electrically conductive, organic material. 8. The nano-construct of claim 1, wherein the electrically conductive material comprises graphite or a conductive polymer. 9. The nano-construct of claim 1, wherein the nanoshell further comprises poly(L-lactide), polyhydroxyalkanoate, polycaprolactone, or combinations thereof 10. The nano-construct of claim 1 further comprising a substrate that includes the optional bioactive agent. 11. The nano-construct of claim 10 wherein the substrate is a small unilamellar vesicle (SUV) encapsulating the bioactive agent. 12. The nano-construct of claim 10 wherein the substrate is a liposome, polymersome, or hybrid vesicle. 13. The nano-construct of the claim 1 wherein the core material further comprises ferromagnetic or magnetic ceramic particles. 14. The nano-construct of claim 1 wherein the core material comprises a peptide, a protein, or a combination of these. 15. The nano-construct of claim 1, further comprising a targeting molecule on the surface of the nano-construct. 16. The nano-construct of claim 15 wherein the targeting molecule is a surface-conjugated ligand for receptors on an inflamed endothelium. 17. The nano-construct of claim 1 in a formulation suitable for systemic delivery or local delivery into a human being. 18. The nano-construct of claim 17 wherein the systemic delivery is injection. 19. The nano-construct of claim 17 wherein the local delivery is delivery by a device comprising a catheter. 20. The nano-construct of claim 1 wherein the optional bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), γ-hiridun, clobetasol, pimecrolimus, imatinib mesylate, or midostaurin, or prodrugs, co-drugs, and a combination thereof. 21. A method comprising: forming a nanoshell around a polymeric core material,wherein the polymeric core material is a degradable polymer or a non-degradable polymer, wherein the non-degradable polymer is selected from the group consisting of poly(N-(3-aminopropyl) methacrylamide), a copolymer of N-(3-aminopropyl)methacrylamide, and a combination thereof, andwherein the nanoshell comprises an electrically conductive material. 22. The method of claim 21 wherein the core material encapsulates at least one bioactive agent. 23. The method of claim 21 wherein the nanoshell is porous. 24. The method of claim 21 further comprising connecting the nano-construct to a substrate. 25. The method of claim 21 wherein the substrate comprises a self-assembled structure. 26. The method of claim 21 wherein the nanoshell comprises gold and has a thickness between about 5 and about 25 nm. 27. The method of claim 21 wherein the nanoshell consists essential of gold and has a thickness between about 5 and about 25 nm. 28. The method of claim 21 wherein the core material has a size between about 150 nm and about 200 nm. 29. The method of claim 21 wherein the core material comprises a peptide, a protein, or a combination of these. 30. The method of claim 21 wherein the nano-construct comprises a targeting molecule on the surface of the nano-construct. 31. The method of claim 29, wherein the targeting molecule is a surface-conjugated ligand against receptors on an inflamed endothelium. 32. The method of claim 21 wherein the nano-construct is in a formulation suitable for systemic delivery or local delivery into a human being. 33. The method of claim 31 wherein the systemic delivery is injection. 34. The method of claim 31 wherein the local delivery is delivery by a device comprising a catheter. 35. The method of claim 22, wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), γ-hirudin, clobetasol, pimecrolimus, imatinib mesylate, or midostaurin, or prodrugs, co-drugs, and a combination thereof. 36. A method of treating, preventing, or ameliorating a medical condition, comprising delivering to a disease site in the body of a human being in need of treatment the nano-construct of claim 1, andcausing the nano-construct to release the bioactive agent. 37. The method of claim 36 wherein the causing comprises irradiating the nano-construct an irradiation, and wherein the nano-construct converts the radiation into heat. 38. The method of claim 37 wherein the irradiation uses a near infrared (NIR) electromagnetic radiation transmitted through a catheter-based fiber-optic. 39. The method of claim 36 wherein the radiation is electromagnetic and is applied outside the body of the subject. 40. The method of claim 36 wherein the delivering comprises allowing the nano-constructs to extravasate through leaky vasculature in the target tissue. 41. The method of claim 36 wherein the nano-construct comprises targeting molecules on the surface of the nano-construct. 42. The method of claim 39 wherein the targeting molecule comprises surface-conjugated ligands against receptors on an inflamed endothelium. 43. The method of claim 38 wherein the nano-construct comprises a surface-disguiseing compound on the surface of the nano-construct that increases the circulation time of the nano-construct. 44. The method of claim 38 wherein the surface-disguiseing compound comprises poly(ethylene glycol). 45. The method of claim 38 wherein medical condition is one or more of atherosclerosis, tumor, a nephrosis, vulnerable plaque, diffuse atherosclerotic disease, diabetic retinopathy, aneurysm, anastomotic hyperplasia, claudication, chronic total occlusion, dysfunctional endothelium, recurring thrombus, or fibrin accumulation. 46. The method of claim 36 wherein the bioactive agent comprises one or more selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine- 1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), γ-hirudin, clobetasol, pimecrolimus, imatinib mesylate, or midostaurin, or prodrugs, co-drugs, and a combination thereof.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.